The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus
The first human glucagon-like peptide-1 analog (liraglutide) was registered in Russia in May 2010. This review contains data on the results of randomizedclinical studies of this preparation applied to the treatment of patients with DM2 as monotherapy and in combination with traditional hypoglycemica...
Main Author: | Marina Vladimirovna Shestakova |
---|---|
Format: | Article |
Language: | English |
Published: |
Endocrinology Research Centre
2010-09-01
|
Series: | Сахарный диабет |
Subjects: | |
Online Access: | https://dia-endojournals.ru/dia/article/viewFile/5497/3295 |
Similar Items
-
Glucagon-like peptide-1 analogues: An overview
by: Vishal Gupta
Published: (2013-01-01) -
Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes
by: Fujishima Yuya, et al.
Published: (2012-09-01) -
Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
by: Campbell RK, et al.
Published: (2010-07-01) -
Treatment with Glucagon-Like Peptide-1 Analogues — a Breakthrough in Diabetes Mellitus Type 2 Therapy
by: V.L. Orlenko, et al.
Published: (2014-05-01) -
Glucagon-like peptide-1 (GLP-1) and liraglutide, a synthetic GLP-1 analog, inhibit inflammation in human aortic endothelial cells via calcium and AMPK dependent mechanisms
by: Krasner, Nadia Marie
Published: (2016)